Retatrutide and Sleep Apnea: What Phase 3 Trials Found
Published · Page updated
Bookmark this page
Save this article in your browser so you can find it again:
- Computer: Press Ctrl+D (Windows) or ⌘+D (Mac).
- iPhone or iPad: In Safari, tap Share, then Add Bookmark.
- Android: In Chrome, open the menu and tap the star.
Other browsers may use a different menu.
Retatrutide sleep apnea research found greater reductions in breathing events than placebo in adults with moderate-to-severe OSA and overweight or obesity. Trial averages do not establish individual outcomes or justify changes to prescribed care. Original study.
Publisher disclosure: Bio Research LLC operates Bio Peptides Labs and sells research materials. This is commercially interested, AI-assisted editorial content, not an independent scientific review. Selected original abstracts, trial records and official sources were checked November 16, 2026. The full journal report and supplement were inaccessible. This article reports research and does not establish the safety, identity or clinical equivalence of catalog products.

What did the retatrutide sleep apnea trials study?
The October 2026 journal report describes randomized, blinded comparisons with placebo over 80 weeks. The OSA studies were subsets within the larger TRIUMPH program: 243 participants without diabetes and 448 with type 2 diabetes. Gastrointestinal adverse events were the most common. Lilly funded the research. Journal abstract.
The registry records specify sleep-study criteria, including an apnea-hypopnea index of at least 15, and distinguish the OSA subsets from the larger trial populations. Some eligible participants used positive airway pressure, while others did not, under protocol-specific conditions. Adding the total enrollment of the parent trials would overstate the number in this OSA analysis. TRIUMPH-1 record, TRIUMPH-2 record.
What is AHI, and how did it change?
The apnea-hypopnea index, or AHI, counts breathing interruptions or reductions per hour of sleep. In the journal's hybrid-treatment analysis, the two higher studied groups had the following average changes:
OSA study | Retatrutide AHI change | Placebo AHI change |
|---|---|---|
Without diabetes | −34.3 and −31.7 events/hour | −9.9 events/hour |
With type 2 diabetes | −24.7 and −25.4 events/hour | −10.3 events/hour |
These are changes from baseline, not final AHI values or placebo-adjusted differences. The hybrid method makes hypothetical assumptions after events suggesting treatment failure and uses a treatment-policy approach elsewhere. Original results and analysis definitions. At the start, the average AHI was 58.6 events/hour in the study without diabetes and 55.9 in the study with diabetes. For the two higher studied groups, the reported reductions relative to placebo were 24.4 and 21.9 events/hour in the first study, and 14.4 and 15.1 events/hour in the second. These are group averages, not final values or guaranteed individual outcomes.
A large change and a low final value answer different questions. As a simple illustration, a reduction of 20 events per hour would have different implications for someone starting at 25 than for someone starting at 60. That example is arithmetic, not a participant result from these trials.
Why do different reports show different numbers?
The November 14 Lilly announcement highlighted the same TRIUMPH program ahead of a November 15 conference session. It reported different headline estimates from those in the journal table above. A later presentation date does not make this an independent replication. November conference announcement.
An analysis method defines the question a trial estimate answers. Readers should keep the population, time point, outcome and handling of treatment changes attached to each number. Comparing two figures without those details can create an apparent contradiction or exaggerate a difference. Our guide to reading research explains how to check these distinctions.
What remains uncertain?
The public abstract cannot replace detailed review of adverse events, withdrawals and sensitivity analyses. Those full tables were not independently reviewed for this article. The trials also do not provide a direct retatrutide-versus-CPAP comparison.
For future research, we would prioritize durable sleep and daytime-function outcomes, safety over longer follow-up, and results in populations outside the studied eligibility criteria. These are editorial research priorities, not studies Bio Peptides Labs claims to conduct.
Is retatrutide approved for sleep apnea?
As of November 19, 2026, retatrutide remains investigational. FDA states that it is not a component of an FDA-approved drug and has not been found safe and effective for any condition. A positive trial and a regulatory approval are separate milestones. FDA information.
Does a lower AHI mean sleep apnea is cured?
No universal conclusion follows from an average change. Final severity, symptoms and individual assessment still matter. The results should not be used as instructions to change prescribed care.
Does this prove retatrutide is better than tirzepatide for OSA?
No. This report compared retatrutide with placebo. A reliable drug comparison requires attention to the actual comparator and comparable trial conditions.
Where should readers go next?
Read the retatrutide side-effects review, the separate knee osteoarthritis article, and our comparison of incretin research.
References
On November 19, 2026, we rechecked the journal abstract, the two registry records and FDA's retatrutide statement. The conference announcement retains its earlier review date. Full trial papers, supplements and patient-level data were not independently reviewed; this was not a systematic review.
